NCT00617201

Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Sharon Walsh · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This placebo-controlled, double-blind, randomized pilot clinical trial will evaluate atomoxetine (Strattera®) for the treatment of cocaine dependence. Cocaine-dependent individuals, who are healthy and are seeking treatment for their substance abuse, will be randomized to receive either atomoxetine (n=25) or a matched-placebo (n=25) during a trial lasting 12 weeks; there will be a double-blind, ascending dose lead-in order to achieve maintenance on the assigned active dose safely. Contingency management procedures will be used to reinforce attendance and compliance with study procedures. Primary outcome measures will include urinalysis data assessing cocaine use.

Conditions

• Substance Abuse

Interventions

Type	Name	Description
DRUG	atomoxetine	Once daily oral dosing
DRUG	placebo	Once daily oral dosing - matched placebo

Timeline

• Start date: 2007-07-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2008-02-15
• Last updated: 2017-08-31
• Results posted: 2012-12-11

Locations

1 site across 1 country: United States